 Almost 1.7bn was wiped from the value of GSK PLC LSE:GSK, NYSE:GSK in opening deals after the drug developer revealed a late-stage study failed to meet its main goal. Blenrep was deemed no better than the current standard of care in helping people with hard-to-treat multiple myeloma, a type of bone marrow cancer. 